{
    "clinical_study": {
        "@rank": "95914", 
        "acronym": "ASCORE", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: Naive of any biologic agent", 
                "description": "Adult patients initiating/treated with Abatacept SC for moderate to severe RA, in usual practice conditions, naive of any biologic agent prior to Abatacept SC initiation"
            }, 
            {
                "arm_group_label": "Cohort 2: Naive of Abatacept", 
                "description": "Adult patients initiating/treated with Abatacept SC for moderate to severe RA, in usual practice conditions, who previously failed one or more biologic agent prior to Abatacept SC initiation"
            }
        ], 
        "biospec_descr": {
            "textblock": "Whole blood (Spanish sub study only)"
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "The purpose of this study is to estimate the retention rate of Abatacept Subcutaneous (SC)\n      over 24 months in routine clinical practice in every participating country depending on the\n      treatment line."
        }, 
        "brief_title": "Long-term Experience With Abatacept SC in Routine Clinical Practice", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Time Perspective: Other Collection of the baseline data collected at abatacept SC\n      initiation, prospectively or retrospectively within maximum 6 months following the first\n      administration.\n\n      Others assessments are collected during the follow up period (maximum of 2 years by patient)\n\n      Biospecimen Retention: None retained excepted for a local sub study (in Spain) where sample\n      with DNA was retained"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Patients \u2265 18 years old at treatment initiation\n\n          -  Patients informed and accepting to participate\n\n          -  Patients diagnosed with established moderate to severe active RA as per the 1987\n             American College of Rheumatology (ACR) criteria/2010 ACR/European League Against\n             Rheumatism (EULAR) Rheumatoid Arthritis Classification Criteria\n\n          -  Patients naive of Abatacept Intravenous (IV) and who at their physician's discretion\n             are initiated with Abatacept SC. In countries were required (e.g. Germany), patients\n             naive of Abatacept IV and who at their physician's discretion have been initiated\n             with Abatacept SC at least 1 month prior to enrollment visit up to 6 months if\n             baseline and disease characteristics data are available\n\n          -  For Cohort 1: Patients naive of biologic prior to Abatacept SC initiation\n\n          -  For Cohort 2: Patients who previously failed one or more biologic agent\n\n        Exclusion Criteria:\n\n          -  As usual in a non-interventional research conducted to assess usual conditions of\n             medical practice, the protocol should not define any specific exclusion criteria\n             except prescription of Abatacept SC in the context of clinical trials. As a\n             consequence, the following exclusion criteria will be applied:\n\n               -  Patients who are currently included in any interventional clinical trial in RA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "RA patients received a biologic therapy"
            }
        }, 
        "enrollment": {
            "#text": "2450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090556", 
            "org_study_id": "IM101-348"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1: Naive of any biologic agent", 
                "Cohort 2: Naive of Abatacept"
            ], 
            "intervention_name": "Abatacept", 
            "intervention_type": "Drug", 
            "other_name": "Orencia"
        }, 
        "intervention_browse": {
            "mesh_term": "Abatacept"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Site 01089"
            }, 
            "facility": {
                "address": {
                    "city": "N\u00fcrnberg", 
                    "country": "Germany", 
                    "zip": "D-90429"
                }, 
                "name": "Local Institution"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "2", 
        "official_title": "Long-term Experience With Abatacept SC in Routine Clinical Practice", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For Site information please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Paul-Ehrlich-Institut", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Switzerland: Swissmedic", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Austria: Federal Office for Safety in Health Care"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Key Primary: Median time and estimation of treatment retention rate of Rheumatoid arthritis (RA) patients treated with Abatacept SC over 24 months in routine clinical practices", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 Months"
            }, 
            {
                "description": "Description include concomitant treatments, dosage and adherence to treatment", 
                "measure": "Co-Primary: Description of how Abatacept SC is prescribed in participating countries for each cohort", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 Months"
            }, 
            {
                "description": "Major characteristics of population of patients (joint population depending on previous prescriptions) include socio-demographic data, medical history, disease history, co-morbidities and clinical measures", 
                "measure": "Co-Primary: Description of the major characteristics of population of patients in real life conditions at Abatacept SC initiation", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 Months"
            }, 
            {
                "description": "Morbi-mortality criteria include clinical measures, Patient Reported Outcomes (PRO), incidence of local site injection reaction, incidence of long-term adverse events (AE), withdrawal from study due to AE and Serious Adverse Events (SAE)", 
                "measure": "Co-Primary: The impact of the Abatacept SC treatment on health status of each population of patients as assessed by morbi-mortality criteria", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090556"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Major determinants including socio-demographic characteristics at treatment initiation, previous biologic treatments, clinical measurements (i.e. Simplified Disease Activity Score based on 28 joints (DAS28), Clinical Disease Activity Index (CDAI), Simple Disease Activity Index (SDAI) and their derived criteria) and PROs such as Health Assessment Questionnaire Disability Index (HAQ-DI) and according to local clinical practices and/or according to local requirements Work Productivity and Activity Impairment Questionnaire:Rheumatoid Arthritis (WPAI:RA), Rheumatoid Arthritis Disease Activity Index (RADAI) or PRO-CLinical ARthritis Activity (PROCLARA) at treatment initiation and/or at studied drug discontinuation", 
                "measure": "Major determinants of Abatacept SC retention rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Distribution of time-to-discontinuation of Abatacept SC therapy for each major determinant of treatment discontinuation", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Retention rate of Abatacept (whatever the formulation, SC or IV) in routine clinical practices", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "inVentiv Health Clinical", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "PharmaNet", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}